AU2002337382B2 - Combination therapy comprising ZD6474 and a taxane - Google Patents

Combination therapy comprising ZD6474 and a taxane Download PDF

Info

Publication number
AU2002337382B2
AU2002337382B2 AU2002337382A AU2002337382A AU2002337382B2 AU 2002337382 B2 AU2002337382 B2 AU 2002337382B2 AU 2002337382 A AU2002337382 A AU 2002337382A AU 2002337382 A AU2002337382 A AU 2002337382A AU 2002337382 B2 AU2002337382 B2 AU 2002337382B2
Authority
AU
Australia
Prior art keywords
taxane
pharmaceutically acceptable
treatment
effective amount
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002337382A
Other languages
English (en)
Other versions
AU2002337382A1 (en
Inventor
Stephen Robert Wedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002337382A1 publication Critical patent/AU2002337382A1/en
Application granted granted Critical
Publication of AU2002337382B2 publication Critical patent/AU2002337382B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002337382A 2001-11-08 2002-11-06 Combination therapy comprising ZD6474 and a taxane Ceased AU2002337382B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0126879.6 2001-11-08
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane

Publications (2)

Publication Number Publication Date
AU2002337382A1 AU2002337382A1 (en) 2003-07-24
AU2002337382B2 true AU2002337382B2 (en) 2008-06-12

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002337382A Ceased AU2002337382B2 (en) 2001-11-08 2002-11-06 Combination therapy comprising ZD6474 and a taxane

Country Status (22)

Country Link
US (2) US20050043395A1 (https=)
EP (1) EP1446124B1 (https=)
JP (1) JP4694127B2 (https=)
KR (1) KR100959607B1 (https=)
CN (1) CN1298328C (https=)
AR (1) AR037346A1 (https=)
AT (1) ATE335488T1 (https=)
AU (1) AU2002337382B2 (https=)
BR (1) BR0213906A (https=)
CA (1) CA2464758C (https=)
CY (1) CY1106259T1 (https=)
DE (1) DE60213845T2 (https=)
DK (1) DK1446124T3 (https=)
ES (1) ES2269769T3 (https=)
GB (1) GB0126879D0 (https=)
IL (2) IL161744A0 (https=)
MX (1) MXPA04004355A (https=)
NO (1) NO328048B1 (https=)
NZ (1) NZ532525A (https=)
PT (1) PT1446124E (https=)
WO (1) WO2003039551A1 (https=)
ZA (1) ZA200403455B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
JP4608215B2 (ja) * 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
JP2008504292A (ja) * 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
WO2022139304A1 (ko) * 2020-12-22 2022-06-30 한미약품 주식회사 Sos1 억제제로서의 신규한 퀴나졸린 유도체 화합물 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
ES2201296T3 (es) * 1996-04-26 2004-03-16 Genaera Corporation Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
AU768027B2 (en) * 1999-02-24 2003-11-27 Uab Research Foundation, The Taxane derivatives for targeted therapy of cancer
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
KR20050056190A (ko) * 2002-08-09 2005-06-14 아스트라제네카 아베 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Eisenhauer E. et al. Int. J. Gynaecological Cancer. 2001. Vol 11 Suppl 1, p68-72. *
Fabbro D. et al. STN database accession No NLM10888033. Anti-cancer Drug Design. 2000. Vol 15 No.1, p17-28. *
Folkman J. et al. Thrombosis & Haemostasis. 2001. Vol 86 No.1, p23-33. *
Moll J. et al. Molecular Medicine Today. 2000. Vol 6 No 5 p188-189 *

Also Published As

Publication number Publication date
ES2269769T3 (es) 2007-04-01
PT1446124E (pt) 2006-12-29
JP2005511597A (ja) 2005-04-28
CN1612738A (zh) 2005-05-04
WO2003039551A1 (en) 2003-05-15
EP1446124A1 (en) 2004-08-18
CY1106259T1 (el) 2011-06-08
HK1068546A1 (en) 2005-04-29
US20050043395A1 (en) 2005-02-24
NO20042365L (no) 2004-06-07
ZA200403455B (en) 2005-08-29
CA2464758C (en) 2010-09-28
DE60213845T2 (de) 2007-03-29
IL161744A0 (en) 2005-11-20
MXPA04004355A (es) 2004-08-11
KR20050043779A (ko) 2005-05-11
KR100959607B1 (ko) 2010-05-27
CN1298328C (zh) 2007-02-07
JP4694127B2 (ja) 2011-06-08
IL161744A (en) 2012-01-31
DK1446124T3 (da) 2006-11-13
DE60213845D1 (de) 2006-09-21
EP1446124B1 (en) 2006-08-09
GB0126879D0 (en) 2002-01-02
ATE335488T1 (de) 2006-09-15
AR037346A1 (es) 2004-11-03
CA2464758A1 (en) 2003-05-15
BR0213906A (pt) 2004-08-31
US20120252827A1 (en) 2012-10-04
NZ532525A (en) 2006-11-30
NO328048B1 (no) 2009-11-16

Similar Documents

Publication Publication Date Title
AU2002337382B2 (en) Combination therapy comprising ZD6474 and a taxane
AU2002337382A1 (en) Combination therapy comprising ZD6474 and a taxane
US20120252826A1 (en) Combination Therapy
AU2003249000B2 (en) Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
HK1068546B (en) Combination therapy comprising zd6474 and a taxane
ES2364030T3 (es) Terapia de combinación de zd6474 con 5-fu y/o cpt-11.
HK1084032B (en) Combination therapy of zd6474 with 5-fu and/or cpt-11

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired